doxazosin mesylate

Functions and indications:
For primary mild and moderate hypertension. For patients who have difficulty controlling blood pressure with medication alone, it can be used in combination with diuretics, beta blockers, calcium antagonists or angiotensin converting enzyme inhibitors (ACEI); symptomatic treatment of benign prostatic hyperplasia.

Usage and dosage:
The dosage and dosage of different dosage forms and specifications of this product may vary. Please read the specific drug instructions for use, or follow the doctor’s advice. Doxazosin mesylate tablets, doxazosin mesylate capsules: 1. The initial dose is 1 mg to reduce the incidence of postural hypotension and first-dose syncope. Postural hypotension often occurs between 2-6 hours after medication, so blood pressure should be measured during this period after the first dose increase. If the drug is discontinued for several days, the drug should be restarted according to the initial treatment plan. 2. Hypertension: The initial dose is 1 mg once a day. According to the patient’s standing blood pressure (based on the measured values ​​2-6 hours and 24 hours after taking the medicine), the dosage can be increased to 2 mg once a day, and then to 4 mg once a day as needed, and then to 6 mg once a day to achieve the ideal antihypertensive effect. Doses exceeding 4 mg increase the possibility of excessive postural effects including syncope, postural dizziness/vertigo and postural hypotension. It is recommended to adjust the dose at intervals of 1-2 weeks, and blood pressure should be measured regularly. Foreign research data suggest that the maximum dose of this product is 16 mg/day, and there is currently no such clinical experience in China. 3. Commonly used doses of doxazosin can be used in patients with renal insufficiency and elderly patients. Benign prostatic hyperplasia: initial dose 1 mg, once a day. According to the patient’s urodynamics and symptoms, the dosage can be increased to 2 mg once a day, and then to 4 mg once a day as needed. It is recommended to adjust the dose at intervals of 1-2 weeks, and blood pressure should be measured regularly. Foreign research data suggest that the maximum dose of this product is 8 mg/day, and there is currently no such clinical experience in China. Doxazosin mesylate sustained-release tablets: 1. When taking this sustained-release tablet, swallow the tablet whole with plenty of water. Do not chew, break or crush it before taking. It is not affected by whether you have eaten or not. The most commonly used dose is 4 mg once a day. The maximum dose used in foreign clinical practice is 8 mg once a day, and there is no such clinical experience in China. 2. Common doses of doxazosin can be used in patients with renal insufficiency and elderly patients. For patients with hepatic insufficiency, see.

Adverse reactions:
The common (>1%) adverse events in the placebo-controlled clinical studies of this product before marketing are shown in the table below. It should be emphasized that adverse events reported in clinical studies are not necessarily caused by the drug itself. 1. Benign prostatic hyperplasia: (1) Abnormalities of the ears and auricular labyrinth: dizziness. (2) Abnormalities of the whole body and administration site: fatigue, peripheral edema. (3) Gastrointestinal abnormalities: abdominal pain, indigestion, nausea. (4) Infections and infestations: influenza-like symptoms, respiratory tract infections, urinary tract infections. (4) Musculoskeletal and connective tissue abnormalities: back pain, myalgia. (5) Nervous system abnormalities: dizziness, headache, drowsiness. (6) Respiratory, thoracic and mediastinal abnormalities: bronchitis, dyspnea, rhinitis. (7) Vascular abnormalities: hypotension, postural hypotension. In clinical studies of patients with benign prostatic hyperplasia, the adverse events of the extended-release tablets (41%) were similar to those of the placebo (39%), but lower than those of the ordinary tablets (54%). The safety profile of elderly patients with benign prostatic hyperplasia (over 65 years old) is similar to that of younger patients. 2. Hypertension: (1) Cardiac abnormalities: palpitations, tachycardia. (2) Ear and auricular labyrinth abnormalities: dizziness. (3) Gastrointestinal abnormalities: abdominal pain, dry mouth, nausea. (4) Systemic and administration site abnormalities: fatigue, chest pain, peripheral edema. (5) Musculoskeletal and connective tissue abnormalities: back pain, myalgia. (6) Vascular abnormalities: postural hypotension. (7) Nervous system abnormalities: dizziness, headache. (8) Respiratory, thoracic and mediastinal abnormalities: bronchitis, cough. (9) Skin and subcutaneous tissue abnormalities: pruritus. (10) Kidney and urinary system abnormalities: cystitis, urinary incontinence. 3. In post-marketing clinical applications, the following adverse events have also been reported: (1) Blood and lymphatic system abnormalities: leukopenia, thrombocytopenia. (2) Ear and auricular labyrinth abnormalities: tinnitus. (3) Eye abnormalities: blurred vision, intraoperative floppy iris syndrome (IFIS). (4) Gastrointestinal abnormalities: gastrointestinal obstruction, constipation, diarrhea, indigestion, flatulence, dry mouth, vomiting. (5) Systemic and administration site abnormalities: fatigue, discomfort, pain. (6) Hepatobiliary abnormalities: cholestasis, hepatitis, jaundice. (7) Immune system abnormalities: allergic reactions. (8) Physical examination: abnormal liver function tests, weight gain. (9) Metabolism and nutrition: loss of appetite. (10) Musculoskeletal and connective tissue abnormalities: joint pain, muscle cramps, muscle weakness. (11) Nervous system abnormalities: postural dizziness, hypoesthesia, paresthesia, syncope, tremor. (12) Mental disorders: agitation, anxiety, depression, insomnia, nervousness. (13) Kidney and urinary system abnormalities: dysuria, hematuria, abnormal urination, frequent urination, nocturia, polyuria, urinary incontinence. (14) Reproductive system and breast abnormalities: male breast development, impotence, abnormal penile erection, retrograde ejaculation. (15) Respiratory, thoracic and mediastinal abnormalities: aggravated bronchospasm, cough, dyspnea, epistaxis. (16) Skin/appendages: hair loss, itching, purpura, rash, urticaria. (17) Vascular abnormalities: hot flashes, hypotension. 4. In addition, after the market launch, some hypertensive patients were reported to have the following adverse events, but these events are generally difficult to distinguish from the symptoms that occur when not taking doxazosin, including bradycardia, tachycardia, palpitations, chest pain, angina pectoris, myocardial infarction, cerebrovascular accident, and arrhythmia.

Contraindications:
1. Patients who are known to be allergic to quinazolines (prazosin and terazosin) or any of the ingredients of this product are contraindicated. 2. Patients who have recently had a myocardial infarction are contraindicated. Patients who have received doxazosin treatment and have a myocardial infarction should decide on the appropriate dose according to their individual circumstances.